Valneva SE (VALN) Free Cash Flow (2021 - 2026)
Valneva SE's (VALN) quarterly Free Cash Flow came in at -$76098.5 in Q1 2026, up 98.86% year-on-year from -$38267.8 in Q1 2025, and up 99.8% quarter-over-quarter from -$37.4 million in Q4 2025.
Valneva SE (VALN) Free Cash Flow (2021 - 2026) Analysis & Trends
Valneva SE has disclosed Free Cash Flow across 6 years of filings, most recently posting -$76098.5 for Q1 2026.
- Free Cash Flow for Q1 2026 came in at -$76098.5, up 98.86% year-over-year; the trailing twelve-month figure through Mar 2026 was -$56.9 million (up 16.71% YoY), and the FY2025 annual result was -$64.2 million, up 25.96% from the prior year.
- Free Cash Flow came in at -$76098.5 for Q1 2026 at Valneva SE, up from -$37.4 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of $63.3 billion in Q3 2023 to a low of -$63.4 billion in Q2 2023.
- The 5-year median for Free Cash Flow is -$22.0 million (2023), against an average of -$40.5 million.
- Peak annual rise in Free Cash Flow reached 76186.67% in 2023, while the deepest fall reached 89973.36% in 2023.
- Valneva SE's Free Cash Flow stood at -$110.7 million in 2022, then gained by 15.17% to -$93.9 million in 2023, then soared by 81.9% to -$17.0 million in 2024, then slumped by 120.08% to -$37.4 million in 2025, then jumped by 99.8% to -$76098.5 in 2026.
- The last three Free Cash Flow figures came in at -$76098.5 (Q1 2026), -$37.4 million (Q4 2025), and -$17.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | -2.49 Mn |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 1.29 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | 63,220.27 |
| 10 | Valneva SE | 167.33 Mn | 44.10 Mn | 5.08 Mn | -76,098.47 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -76,098.47 |
| Mar 31, 2026 | -76,098.47 |
| Dec 31, 2025 | -37.40 Mn |
| Dec 31, 2025 | -37.40 Mn |
| Sep 30, 2025 | -17.86 Mn |
| Sep 30, 2025 | -17.86 Mn |
| Jun 30, 2025 | -1.55 Mn |
| Jun 30, 2025 | -1.55 Mn |
| Mar 31, 2025 | -6.66 Mn |
| Mar 31, 2025 | -6.66 Mn |
| Dec 31, 2024 | -16.99 Mn |
| Dec 31, 2024 | -16.99 Mn |
| Sep 30, 2024 | -4.54 Mn |
| Sep 30, 2024 | -4.54 Mn |
| Jun 30, 2024 | -40.11 Mn |
| Jun 30, 2024 | -40.11 Mn |
| Mar 31, 2024 | -25.86 Mn |
| Mar 31, 2024 | -25.86 Mn |
| Dec 31, 2023 | -93.89 Mn |
| Dec 31, 2023 | -93.89 Mn |